Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis

Status Recruiting

Clinical Trial Summary

This study aims to explore the role of dagliflozin in preserving the residual renal function(RRF) in peritoneal dialysis (PD) patients.

Clinical Trial Description

Residual renal function (RRF) plays the role of removing water and body metabolic wastes, as well as secretion of erythropoietin and promotion of vitamin D absorption, which can maintain the stability of the internal environment. Several studies have demonstrated that preservation of RRF in PD patients reduces complications, increases dialysis adequacy and decreases mortality. In addition, residual renal function is an important factor in the technique survival. Methods to protect residual renal function in peritoneal dialysis patients include controlling blood pressure, controlling blood glucose, adjusting dialysis prescription, and using renin-angiotensin inhibitors. However, the above methods currently play only a limited role. Sodium-dependent glucose transporters 2 (SGLT2) inhibitors are drugs used in the treatment of type 2 diabetes mellitus that inhibit the reabsorption of glucose by the kidneys, causing glucose to be excreted in the urine and lowering blood glucose. Studies have demonstrated that SGLT2 inhibitors also attenuate renal tubular injury, reduce the excretion of proteinuria, and have a protective effect on RRF in non-dialysis patients with chronic kidney disease. However, there are no clinical studies demonstrating whether the use of SGLT2 inhibitors in peritoneal dialysis patients is renal protective. In light of this, this study introduces dagliflozin orally to PD patients over a 24-week period to explore its protective effects on RRF and cardiac health, with participants being randomly divided into a dagliflozin group and a control group. The results of this study will be beneficial in informing the clinical practice of SGLT2 inhibitors and improving dialysis outcomes in PD patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06398977
Study type	Interventional
Source	Sichuan Academy of Medical Sciences
Contact	Jin Chen, MD
Phone	0086-28-87393195
Email	jessicakxcj@uestc.edu.cn
Status	Recruiting
Phase	N/A
Start date	March 11, 2024
Completion date	December 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04034628` - Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion
Completed	`NCT03569410` - The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients	N/A
Completed	`NCT04302649` - Dialysate Temperature in Peritoneal Dialysis	Phase 4
Enrolling by invitation	`NCT05250752` - Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment	Phase 2
Recruiting	`NCT03563898` - Feasibility and Safety in the Management of Fluid Overload in Peritoneal Dialysis Patients Through Sweat Stimulation With the Use of Portable Sauna Bath, Pilot Study	N/A
Recruiting	`NCT03046511` - Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter.	Phase 3
Not yet recruiting	`NCT05224466` - Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients
Completed	`NCT03458819` - EMT in Peritoneal Dialysis Patients
Not yet recruiting	`NCT06045858` - SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN PERITONEAL DIALYSIS PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION: A PROSPECTIVE, RANDOMISED, OPEN-LABEL, BLINDED END-POINT TRIAL (APIDP2)	Phase 3
Active, not recruiting	`NCT04034966` - Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis	N/A
Completed	`NCT04923295` - The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients	N/A
Not yet recruiting	`NCT05715814` - meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis	Phase 3
Recruiting	`NCT03148002` - Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation	Phase 4
Recruiting	`NCT04572724` - The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value	Phase 4
Completed	`NCT05797181` - The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment	N/A
Recruiting	`NCT01893710` - International (Pediatric) Peritoneal Biobank
Completed	`NCT03382444` - The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD
Completed	`NCT04046263` - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients	Phase 4
Completed	`NCT03759002` - Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.
Completed	`NCT04176627` - Assessing Fluid Status of Peritoneal Dialysis Patients With Assistance of Lung Ultrasound

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms